NCT03481296 is a NA clinical trial of Advanced Control in Colorectal Cancer, sponsored by University of California, Irvine.

Who is sponsoring NCT03481296?

NCT03481296 is sponsored by University of California, Irvine.

What drugs are being tested in NCT03481296?

Interventions in NCT03481296: Advanced Control, Culturally-Adapted Decision Support Navigation Intervention.

What condition does NCT03481296 study?

NCT03481296 studies Colorectal Cancer.

Is NCT03481296 still recruiting?

NCT03481296 is currently completed. Last updated 3 July 2023.

Last reviewed 2023-07-03 · How we verify

NCT03481296

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Screening TO Prevent ColoRectal Cancer (STOP CRC) Among At-Risk Chinese and Korean American Primary Care Patients

Completed NA Last updated 3 July 2023

What this trial tests

NA trial testing Advanced Control in Colorectal Cancer in 400 participants. Completed in 30 June 2021.

Timeline

20 August 2018

Primary endpoint
30 June 2021

30 June 2021

Quick facts

Lead sponsor	University of California, Irvine
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	400
Start date	20 August 2018
Primary completion	30 June 2021
Estimated completion	30 June 2021
Sites	1 location across United States

Drugs / interventions tested

Advanced Control
Culturally-Adapted Decision Support Navigation Intervention

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

University of California, Irvine

Who can join

Adults 50 to 75, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the study is to conduct a randomized controlled trial to determine the impact of a multi-level culturally-sensitive decision support intervention on colorectal cancer screening adherence among 400 Chinese and Korean American primary care patients.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

The association of acculturative stress with self-reported sleep disturbance and sleep duration among Asian Americans.
Lee S, Ryu S, Lee GE, Kawachi I, et al · · 2022 · cited 22× · PMID 34922392 · DOI 10.1093/sleep/zsab298
The Mediating Role of Sleep Disturbance on the Association Between Stress and Self-Rated Health Among Chinese and Korean Immigrant Americans.
Morey BN, Ryu S, Shi Y, Lee S. · · 2023 · cited 6× · PMID 36701271 · DOI 10.5888/pcd20.220241
Acculturation and Cardiometabolic Abnormalities Among Chinese and Korean Americans.
Morey BN, Ryu S, Shi Y, Park HW, et al · · 2023 · cited 6× · PMID 35705844 · DOI 10.1007/s40615-022-01347-x
Risk of Sleep Apnea Is Associated with Abdominal Obesity Among Asian Americans: Comparing Waist-to-Hip Ratio and Body Mass Index.
Lee S, Ryu S, Lee GE, Redline S, et al · · 2024 · cited 4× · PMID 36622567 · DOI 10.1007/s40615-022-01507-z
Risk of sleep apnea associated with higher blood pressure among Chinese and Korean Americans.
Morey BN, Shi Y, Ryu S, Redline S, et al · · 2024 · PMID 38303653 · DOI 10.1080/13557858.2024.2311417

Verify or expand the search:

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other University of California, Irvine trials

Trials by the same sponsor.

NCT06952725 — Chatbot for Online Support Groups to Treat Tobacco Addiction · NA · not yet recruiting
NCT07167862 — Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound · Phase 4 · not yet recruiting
NCT07527325 — Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma · Phase 2 · not yet recruiting
NCT07391891 — Musical Mindfulness for Pain in the ED Waiting Room · NA · not yet recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03481296 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Irvine
Last refreshed: 3 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03481296.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing